Amplia Therapeutics Share Price and Company Fundamentals

0.002 (2.299%)
52 week
0.08 - 0.18

Last traded: Today at 12:10 AM

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield




Market cap


Enterprise value


Company profile

Primary activities Pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
Industry / Sector Biotechnology / Healthcare
Mailing address 350 Queen Street Level 17 Melbourne VIC 3000 Australia
Phone / Fax /


More: Amplia Therapeutics Dividend history, yield and payout ratio

Dividend yield


Dividend amount


Payout ratio


Amplia Therapeutics paid $0.00 dividend and the ex-dividend date was .The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.ATX dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.

ATX's forward dividend amount is $ and the forward dividend yield is . A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.

Company Executives

As of Feb 2023, following are the company executives and directors listed on Amplia Therapeutics.

Name Title Age Total Pay
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director 57 22k
Mr. Hamish George Chief Financial Officer
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec. 62
Dr. Frank Gelder Founding Scientist
Dr. James A. Taylor Ph.D. Trials Consultant 61
Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. Trials Consultant 74
Dr. Benjamin M. Segal Clinical Consultant
Dr. Frederick E. Reno Ph.D. Toxicology Consultant

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Amplia Therapeutics is and its enterprise value is .

The ATX's stocks Beta value is 0.37 making it 63% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Amplia Therapeutics (ATX)

Amplia Therapeutics (ASX:ATX) Frequently Asked Questions

1. What is Amplia Therapeutics's Stock Symbol?

Amplia Therapeutics trades on ASX under the ticker symbol "ATX".

2. What is Amplia Therapeutics's stock price today?

One share of ATX stock can currently be purchased for approximately $0.089.

3. How can I contact Amplia Therapeutics?

Amplia Therapeutics's mailing address is 350 Queen Street Level 17 Melbourne VIC 3000 Australia. The company can be reached via phone at .

4. What is Amplia Therapeutics's official website?

The official website of Amplia Therapeutics is

5. Which share registry manages Amplia Therapeutics's stock?

Amplia Therapeutics's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.